Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe Ulcerative Colitis ...Middle East

ADS051 was safe and well-tolerated at all doses with no safety signal observed Clinical remission was achieved in 22% of patients after only 28 days on drug CONCORD, Mass., Oct. 22, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating...

Hence then, the article about adiso therapeutics announces positive topline data from phase 1b study of ads051 for the treatment of moderate to severe ulcerative colitis was published today ( Sunday 22/10/2023 - 10:04 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe Ulcerative Colitis )

Also on site :

• Amazon’s ‘Powerful’ Electric Scrub Brush Helps Reach the Hard-to-Clean Spots — Tackle Grime Now for 40% Less
• Quote of the Day: Harper Lee on the Power of Empathy and Seeing the World Through Someone Else’s Eyes
• Land sold for Kushner-backed Albania resort suspected of forged deeds